WNT3A and glioblastoma: To assess the therapeutic potential of blocking sICAM‐1 or WNT3A for the mesenchymal shift and infiltration of GBM, we treated either ICAM‐1 or WNT3A neutralizing antibody to irradiated U87MG cells which were cocultured with THP‐1.